ONIVYDE plus carboplatin for advanced gut neuroendocrine cancer
Part of Cancer clinical trials.
This Phase 1/2 study tests ONIVYDE® (a type of irinotecan drug) combined with carboplatin in people with advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma. The goal is to see how well the treatment works and how safely it can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed as advanced or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma on biopsy
- You have either not had chemotherapy before, or your last chemotherapy was given more than 6 months before your cancer came back
- There must be at least one measurable tumor spot on scans
- You are age 20 to 80, and your general health score (ECOG) is 0 to 1
- Your kidneys, liver, and blood counts must be within allowed limits
- You must have a heart rhythm test (ECG) that is normal or not clinically concerning
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether cabozantinib plus lanreotide can slow or shrink gastroenteropancreatic neuroendocrine tumors that have gotten worse despite previous treatments. If you qualify, you’ll be closely monitored for tumor response and side effects.
This trial tests a chemotherapy drug called irinotecan liposomes for people with high-grade neuroendocrine tumors or neuroendocrine cancers of the digestive system. The goal is to see if this treatment can help shrink or control the tumors.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) in people whose advanced neuroendocrine carcinoma has stopped responding to standard first-line treatment. The goal is to see if this special formulation can help slow or shrink the cancer.
This study looks at how well a chemotherapy combination (Onivyde plus 5-FU and leucovorin) works for people with advanced pancreatic cancer in China. It may help your doctor understand if this treatment is effective for you, especially if you have already tried a gemcitabine-based treatment.
This study watches how safe and effective a combination of chemotherapy drugs (ONIVYDE, 5-FU, and leucovorin) is for people with pancreatic cancer that has spread. It's for patients who have already tried gemcitabine without success, and the treatment is given as part of regular care, not as a separate experimental treatment.
This Phase 2 study tests a chemotherapy approach in people with metastatic grade 3 (high-grade) neuroendocrine cancer or a related rare mixed tumor. It may help shrink tumors and control disease when standard first treatments have not yet been given.
Hear when a new GEP-NET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.